From data to decision: Why primary literature alone isn't enough for Oncology

Primary literature is essential for understanding oncology. But it doesn’t tell you what to do next. Living Algorithms bridge that gap by translating trial data into clear, practical treatment decisions at the point of care.

The promise and limits of primary literature

Oncology runs on data. Clinical trials define standards of care. Papers shape how we think about treatment. New evidence constantly changes the landscape.

Tools that surface primary literature have become increasingly powerful. You can quickly find studies, review results, and understand the context behind a recommendation.

That’s incredibly valuable.

But when you’re preparing to see a patient, the question is different. You're not asking: "what studies exist?"

You're asking: what should I do for this patient, right now?

Why data alone doesn’t answer the clinical question

Primary literature gives you the building blocks:

• Trial design

• Inclusion and exclusion criteria

• Endpoints like PFS and OS

• Toxicity data
  

But turning that into a decision requires multiple steps:

1. Interpreting results across different trials

2. Comparing regimens that were never studied head-to-head

3. Adjusting for a patient who doesn’t match trial criteria

4. Translating outcomes into a real treatment plan

In practice, this means you often:

1. Open multiple papers

2. Cross-reference guidelines

3. Rely on prior experience or colleague input

Even with strong tools, the final synthesis is still on you.

The "last mile" problem in oncology

There's a gap between information and action. You can think of it as the "last mile." Literature gets you to understanding, but not to a decision.

This gap becomes most obvious in everyday scenarios:

Second and third line treatment

You know the first line well. But after progression, options multiply and data becomes less clear.

Rare or complex cases

You may find relevant studies, but none match your patient exactly.

Time pressure

You have limited time before clinic. You need answers quickly, not a stack of papers to interpret.

Real-world nuance

Trials don't capture everything:

• Dose adjustments

• Comorbidities

• Polypharmacy

• Practical monitoring
  

These details often sit outside the literature.

When literature leaves you with more questions

In some cases, reviewing the data doesn’t simplify the decision. It complicates it. You might find conflicting results across studies, no clear head-to-head comparisons, uncertainty about duration of therapy or gaps in evidence altogether.

Clinicians often refer to these as "data-free zones."

In these moments, the challenge isn’t lack of access to information. It’s lack of clear direction.

From evidence to action: what's missing

To move from data to decision, you need more than studies. You need:

1. A structured way to compare options

2. Context for when to use each therapy

3. Practical details on how to implement treatment

4. Insight into real-world considerations
   

This is where traditional literature tools stop.

How Living Algorithms close the gap

Living Algorithms are designed to take the evidence and turn it into something usable at the point of care. Instead of presenting isolated studies, they organize information into a decision pathway.

You start with the patient:

• Biomarker

• Stage

• Prior treatments

• Key clinical features
  

From there, the algorithm shows you what to do next.

What that looks like in practice

Structured treatment pathways

Clear sequencing from first line to later lines, without having to piece together multiple sources.

Integrated evidence

Key trial data is still there:

• PFS and OS

• Hazard ratios

• Key caveats

But it's tied directly to the decision, not presented in isolation.

Practical details you can act on

Instead of stopping at “this drug is an option,” you see:

• Dosing and schedules

• Real-world adjustments

• Dose modifications

• Monitoring requirements
  

These are often the details clinicians have to look up separately.

Real-world context

Living Algorithms incorporate the nuance that doesn’t always appear in trials:

• Relative contraindications

• Use with caution scenarios

• Common pitfalls in practice

Clarity in uncertainty

In areas where evidence is limited, the algorithm makes that explicit. You can quickly see:

• Where data is strong

• Where it’s evolving

• Where expert interpretation plays a role
  

Not replacing literature, but completing it

Primary literature remains essential. It's how we advance the field, validate treatments and understand mechanisms. Living Algorithms don't replace that foundation. They sit on top of it, translating evidence into decisions.

A more efficient workflow

In practice, this changes how you prepare for clinic. Instead of:

• Searching for papers

• Interpreting results

• Cross-referencing multiple tools
  

You can:

• Identify the relevant pathway

• Review key evidence

• Confirm practical details

• Move into the patient conversation
  

All within a single workflow.

From uncertainty to confidence

Even when you already have a plan in mind, there's value in confirming it quickly.

Living Algorithms help you:

• Validate your approach

• Double-check important details

• Identify considerations you might have missed

That shift from uncertainty to confidence matters, especially in complex cases.

Bottom line

Primary literature tells you what we know, but it doesn’t always tell you what to do. In modern oncology, where decisions are complex and time is limited, that distinction matters.

Living Algorithms bridge that gap, helping you move from data to decision with clarity and speed.

Try it with a patient case

The next time you’re reviewing a study or preparing for a consult, ask yourself: "What do I actually need to decide?"

Then try approaching that question through a structured pathway instead of a list of papers.

You may find the answer faster than you expect.